By Annette Pinder

For decades, pancreatic cancer has been considered one of the deadliest and most difficult cancers to treat. Often called a “silent” disease because symptoms usually appear late, it has only about a 12% five-year survival rate. But researchers are now reporting breakthroughs that many experts say could mark a turning point in the fight against this devastating illness.

A recent New York Times article described how an “impossible” scientific idea — targeting a cancer-driving mutation called KRAS — is finally showing dramatic results. For years, scientists considered KRAS essentially “undruggable.” The mutation appears in more than 90% of pancreatic cancers and acts like a stuck accelerator pedal, constantly signaling cancer cells to grow. Despite decades of effort, researchers could not find a reliable way to stop it.

Now, new experimental drugs are changing that.

According to the Washington Post, one of the most promising medications, called daraxonrasib, nearly doubled survival in patients with advanced pancreatic cancer in clinical trials. Patients taking the drug lived a median of 13.2 months, compared with 6.7 months for those receiving standard chemotherapy. Researchers say these results are remarkable for a cancer that has historically had very limited treatment success.

The Washington Post notes that other innovative approaches are also generating excitement. Scientists are studying personalized mRNA vaccines designed to train a patient’s immune system to recognize and attack pancreatic cancer cells. Early trials by BioNTech and Genentech showed especially encouraging long-term survival in some patients.

Artificial intelligence is also playing an increasingly important role. Researchers recently developed an AI system that can detect subtle pancreatic abnormalities on CT scans up to three years before doctors typically diagnose pancreatic cancer. Earlier detection could dramatically improve survival because pancreatic cancer is far more treatable in its earliest stages, according to Live Science.

Meanwhile, the New York Post notes that additional laboratory discoveries are helping researchers better understand how pancreatic cancer spreads. Scientists at Cold Spring Harbor Laboratory identified genetic pathways that may enable doctors to “intercept” the disease before it becomes more aggressive.

Experts caution that these treatments are still under study and are not yet cures. Some therapies can also cause significant side effects. However, many oncologists believe the field has entered a new era after decades of frustration and limited progress.

The excitement surrounding these discoveries stems from researchers finally finding ways to attack pancreatic cancer at its biological roots. Instead of relying solely on chemotherapy, future treatment may involve combinations of targeted drugs, vaccines, immunotherapies, and earlier-detection tools working together. For patients and families affected by pancreatic cancer, that shift represents something that has long been in short supply: real hope.